在RR-DTC中从共享的现实生活环境中获得一线的伦瓦替尼和索拉费尼
Vincenzo Marotta1, Anna Tortora2, Mariafelicia Valeriani3
1Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
Endocrine-related cancer
|October 6, 2025
概括
伦瓦提尼布在耐放射性分化甲状腺癌 (RR-DTC) 中表现出比索拉费尼布更好的无进展生存率和反应率. 然而,伦瓦提尼布有更多的副作用,而索拉芬尼布更易于管理.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 抗放射性分化甲状腺癌 (RR-DTC) 需要有效的全身疗法.
- 伦瓦提尼布和索拉费尼布是RR-DTC的第一线激酶抑制剂.
- 在同质人群中进行的直接比较研究有限.
研究的目的:
- 为了比较伦瓦提尼布与索拉费尼布在未经治疗的RR-DTC患者中的疗效和安全性.
- 在现实世界,均的临床环境中评估结果.
主要方法:
- 意大利坎帕尼亚两所机构的回顾性研究.
- 包括48名RR-DTC患者 (24名伦瓦替尼布,24名索拉芬尼布).
- 对无进展生存 (PFS),总生存 (OS),客观反应率 (ORR) 和不良事件的分析.
主要成果:
- 伦瓦替尼布组的PFS中位数显著更长 (30个月与10个月相比),ORR更高 (P < 0.001).
- 索拉芬尼布组呈现出更先进的疾病,更高的症状率和瘤负担.
- 减少剂量/中断剂量更频繁地与lenvatinib;索拉芬尼比更容易管理.
结论:
- 伦瓦提尼布在一线RR-DTC中表现出优越的抗瘤活性 (PFS,ORR) 与索拉费尼布相比.
- 在多变量分析中,伦瓦提尼布的整体生存益处在统计学上并不显著.
- 索拉费尼布提供了更好的耐受性和可管理性,尽管在基线时患者的病情不那么先进.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


